Updates on the treatment of essential hypertension: A summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors

Journal of Managed Care Pharmacy

Volumn 17, Issue 8, 2011, Pages

  Powers, Benjamin ^a   Greene, Laurence ^b   Balfe, Lisa M ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b PRIME Education Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; COUGHING; DIABETES CONTROL; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; HEADACHE; HEALTH CARE PERSONNEL; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MANAGED CARE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

EID: 84856297494     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.s8.1     Document Type: Article

References (113)

1. Egan BM, Zhao Y, Axon RN. U.S. trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-50. Available at: http://jama.ama-assn.org/content/303/20/2043.full.pdf+html. Accessed August 10, 2011.
2. World Health Organization. World health report 2002: reducing risks, promoting healthy life. World Health Organization. Geneva, Switzerland. Available at: www.who.int/whr/2002. Accessed August 10, 2011.
3. No authors listed. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153(2):154-83.
4. No authors listed. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157(21):2413-46. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/. Accessed September 12, 2011.
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52. Available at: http://hyper.ahajournals.org/content/42/6/1206.full.pdf+html. Accessed September 12, 2011.
6. Wright JD, Hughes JP, Ostchega Y, et al. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001-2008. National health statistics reports; no 35. Hyattsville, MD: National Center for Health Statistics. 2011. Available at: www.cdc.gov/nchs/data/nhsr/nhsr035.pdf. Accessed August 12, 2011.
7. Ma J, Stafford RS. Screening, treatment, and control of hypertension in U.S. private physician offices, 2003-2004. Hypertension. 2008;51(5):1275-81. Available at: http://hyper.ahajournals.org/content/51/5/1275.full.pdf+html. Accessed August 10, 2011.
8. Cheng JW. Aliskiren: renin inhibitor for hypertension management. Clin Ther. 2008;30(1):31-47.
9. Chou R, Helfand M, Carson S. Drug class review on angiotensin converting enzyme inhibitors. Final report. June 2005. Available at: http://derp.ohsu.edu/about/final-document-display.cfm#tab-2. Accessed August 10, 2011.
10. Furmaga E, Glassman P, Rhodes S, et al. Drug class review on angiotensin II receptor antagonists. Final report. February 2006. Available at: http://derp.ohsu.edu/about/final-document-display.cfm#tab-2. Accessed August 10, 2011.
11. Matchar DB, McCrory DC, Orlando LA, et al. Comparative effectiveneness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension. Comparative effectiveness review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Rockville, MD: Agency for Healthcare Research and Quality. November 1, 2007. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-andreports/?productid=48&pageaction=displayproduct. Accessed August 19, 2011.
12. Shekelle P, Newberry S, Maglione M, et al. Assessment of the need to update comparative effectiveness reviews: report of an initial rapid program assessment (2005-2009). Rockville, MD: Agency for Healthcare Research and Quality; 2009. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/125/331/2009_0923UpdatingReports.pdf. Accessed September 17, 2011.
13. Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update. Comparative effectiveness review No. 34. (Prepared by The Duke Evidencebased Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 13, 2011. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=696. Accessed August 18, 2011.
14. Atkins D, Chang S, Gartlehner G, et al. Assessing the applicability of studies when comparing medical interventions. Agency for Healthcare Research and Quality; January 2011. Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication No. 11-EHC019-EF. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guidesreviews-and-reports/?pageaction=displayproduct&productid=603. Accessed September 17, 2011.
15. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventionsagency for healthcare research and quality and the effective healthcare program. J Clin Epidemiol. 2010;63(5):513-23. GRADE Working Group. Available at: http://www.gradeworkinggroup.org/. Accessed August 12, 2011.
16. Derosa G, Cicero AF, Ciccarelli L, et al. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 2003;25(7):2006-21.
17. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21(9):1034-39.
18. Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [erratum appears in Clin Ther. 2004;26(7):1185] Clin Ther. 2004;26(6):855-65.
19. Menne J, Farsang C, Deák L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens. 2008;26(9):1860-67.
20. Ruilope L, Jäger B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223-29.
21. Scaglione R, Argano C, Di Chiara T, et al. Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens. 2007;21:307-15.
22. Schram MT, van Ittersum FJ, Spoelstra-de Man A, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a doubleblind, randomized clinical trial. J Hum Hypertens. 2005 Jun;19(6):429-37. Available at: http://www.nature.com/jhh/journal/v20/n8/pdf/1002025a.pdf. Accessed July 7, 2011.
23. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Hum Hypertens. 2006;8(9):634-41. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-6175.2006.05504.x/pdf. Accessed July 7, 2011.
24. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin. 1999;15(1):9-14.
25. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. [erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731]. N Engl J Med. 2004;351(19):1952-61. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa042274. Accessed July 7, 2011.
26. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483-89.
27. Breeze E, Rake EC, Donoghue MD, Fletcher AE. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. J Hum Hypertens. 2001;15:857-62. Available at: http://www.nature.com/jhh/journal/v15/n12/pdf/1001282a.pdf. Accessed July 7, 2011.
28. Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther. 2002;24(1):126-38.
29. De Rosa ML, Cardace P, Rossi M, et al. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens. 2002;16(2):133-40. Available at: http://www.nature.com/jhh/journal/v16/n2/pdf/1001305a.pdf. Accessed July 7, 2011.
30. Deyneli O, Yavuz D, Velioglu A, et al. Effects of ACE inhibition and angiotension II receptor blockade on glomerular basement membrane protein excretion and change selectivity in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2006;7(2):98-103.
31. Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J Hum Hypertens. 1999;13(6):413-17.
32. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(4 Pt 1):316-20.
33. Fogari R, Zoppi A, Preti P, et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens. 2001;14(9 Pt 1):921-26.
34. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20:177-85.
35. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):15-24.
36. Hosohata K, Saito S, Asayama K, Ohkubo T, Kikuya M, Metoki H, et al. Progress report on The Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study: status at February 2004. Clin Exp Hypertens. 2007;29:69-81.
37. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999;17(2):293-302.
38. Kloner RA, Neutel J, Roth EM, et al. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the amlodipine diabetic hypertension efficacy response evaluation trial. Ann Pharmacother. 2008;42:1552-62.
39. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58(2):762-69. Available at: http://www.nature.com/ki/journal/v58/n2/pdf/4491743a.pdf. Accessed July 7, 2011.
40. Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol. 1997;80(12):1613-15.
41. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):25-32.
42. McInnes GT, O'Kane KP, Istad H, et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000;14(4):263-69.
43. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12(3):203-08.
44. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440- Available at: http://www.bmj.com/content/321/7274/1440.full.pdf. Accessed July 7, 2011.
45. Naidoo DP, Sareli P, Marin F, et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther. 1999;16(5):187-99.
46. Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J. 2009;50(4):501-12. Available at: http://www.jstage.jst.go.jp/article/ihj/50/4/501/_pdf. Accessed September 17, 2011.
47. Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6(3):161-66.
48. Onal IK, Altun B, Onal ED, Kirpantur A, Gul Oz S, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009;20(4):369-72.
49. Rabbia F, Silke B, Carra R, et al. Heart rate variability and baroreflex sensitivity during fosinopril, irbesartan and atenolol therapy in hypertension. Clin Drug Investig. 2004;24(11):651-59.
50. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens. 2007;20:184-89.
51. Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2005;23(2):435-44.
52. Saito S, Asayama K, Ohkubo T, et al. The second progress report on the Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study. Blood Press Monit. 2004;9(5):243-47.
53. Sanchez RA, Masnatta LD, Pesiney C, Fischer P, Ramirez AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens. 2008;26(12):2393-98.
54. Sengul AM, Altuntas Y, Kürklü A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract. 2006;71:210-19.
55. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricularhypertrophy in endstage renal disease. Nephron. 2002;90(3):256-61.
56. Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995;17(5):911-23.
57. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res. 2005;28(2):111-16.
58. Zhu S, Liu Y, Wang L, et al. Transforming growth factor-(beta)(1) is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008;23(9):2841-46. Available at: http://ndt. oxfordjournals.org/content/23/9/2841.full.pdf+html. Accessed July 7, 2011.
59. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol. 2010;42:153-56. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937316/. Accessed July 7, 2011.
60. Avanza AC Jr, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol. 2000;74(2):103-17. Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2000000200001&lng=en&nrm=iso. Accessed July 7, 2011.
61. Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol. 2005;28(6):298-302.
62. Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol. 2003;92(5):621-24.
63. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281-86.
64. Guntekin U, Gunes Y, Tuncer M, et al. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients. Adv Ther. 2008;25(8):775-86.
65. Kavgaci H, Sahin A, Onder Ersoz H, et al. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract. 2002;58(1):19-25.
66. Koylan N, Acarturk E, Canberk A, et al. Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study. Blood Press Suppl. 2005;1:23-31.
67. Matsuda H, Hayashi K, Saruta T. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens. 2003;17(4):271-76.
68. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens. 2003;16(6):439-44.
69. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44(2):362-68.
70. Shand BI. Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension. J Hum Hypertens. 2000;14(5):305-09.
71. Shand BI, Lynn KL. A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease. Clin Nephrol. 2000;54(5):427-28.
72. Sonoda M, Aoyagi T, Takenaka K, et al. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J. 2008;49(1):95-103. Available at: http://www.jstage.jst.go.jp/article/ihj/49/1/95/_pdf. Accessed July 7, 2011.
73. Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, et al. Endothelial vascular function in hypertensive patients after reninangiotensin system blockade. J Clin Hypertens. 2006;8(11):803-9; quiz 10-1.
74. Spinar J, Vitovec J, Soucek M, et al. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitr Lek. 2009;55(5):481-88.
75. Verdecchia P, Schillaci G, Reboldi GP, et al. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. Blood Press Monit. 2000;5(3):187-93.
76. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3(6):999-1005. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350135/pdf/VHRM_0306-999.pdf. Accessed July 7, 2011.
77. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002;20(11):2293-300.
78. Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens. 1996;14(2):263-70.
79. Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrology Dialysis Transplantation. 1997;12 Suppl 2:19-23.
80. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995;13(11):1343-51.
81. Hermida RC, Ayala DE, Khder Y, et al. Ambulatory blood pressurelowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, openlabel, blinded end-point trial. Clin Ther. 2008;30(1):108-20.
82. Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan, medoxomil, and ramipril in elderly patients with mild to moderate essential hypertension: The ESPORT study. J Hypertens. 2010;28(11):2342-50.
83. Amerena J, Pappas S, Ouellet JP, et al. ABPM comparison of the antihypertensive profiles of telmisartan and enalapril in patients with mild-tomoderate essential hypertension. J Int Med Res. 2002;30(6):543-52.
84. Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59(12):863-68.
85. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177-85.
86. Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens Suppl. 1995 Jul;13(1):S35-41.
87. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000;13(5 Pt 1):504-11.
88. Roca-Cusachs A, Oigman W, Lepe L, et al. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol. 1997;52(6):495-506.
89. Ragot S, Ezzaher A, Meunier A, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens. 2002;16(12):865-73.
90. Lacourciere Y, Neutel JM, Davidai G, et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-tomoderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19(1):104-12.
91. Williams B, Gosse P, Lowe L, et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24(1):193-200.
92. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26(3):589-99.
93. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial. J Hum Hypertens. 2010;24(9):600-08. 2009 Dec 24.
94. Solomon SD, Appelbaum E, Manning WJ, et al.; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530-37. Available at: http://circ.ahajournals.org/content/119/4/530.full.pdf+html. Accessed September 6, 2011.
95. Andersen K, Weinberger MH, Constancem CM, et al. Comparative effects of aliskiren based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10(3):157-67.
96. Barnett AH, Bain SC, Bouter P, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. [erratum appears in N Engl J Med. 2005;352(16)1731]. N Engl J Med. 2004;351(19):1952-61. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa042274. Accessed September 17, 2011.
97. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):9-14.
98. Breeze E, Rake EC, Donoghue MD, et al. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. J Hum Hypertens. 2001;15(12):857-62.
99. De Rosa ML, Cardace P, Rossi M, et al. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens. 2002;16(2):133-40. Available at: http://www.nature.com/jhh/journal/v16/n2/pdf/1001305a.pdf. Accessed July 7, 2011.
100. Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J Hum Hypertens. 1999;13(6):413-17.
101. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26- week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):15-24.
102. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999;17(2):293-302.
103. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15(1):25-32.
104. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16(8):569-75.
105. Robles NR, Angulo E, Grois J, et al. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail. 2004;26(4):399-404.
106. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093-100.
107. Spoelstra-de Man AM, van Ittersum FJ, Schram MT, et al. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. J Hum Hypertens. 2006;20(8):599-611.
108. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007;98(1):57-63.
109. Xu D, Liu J, Ji C, et al. Effects of telmisartan on hypertensive patients with dyslipidemia and insulin resistance. J Geriatr Cardiol. 2007;4(3):149-52.
110. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol. 1999;47(1):111-14. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014204/pdf/bcp0047-0111.pdf. Accessed September 17, 2011.
111. Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23(5):715-26.
112. Sato A, Tabata M, Hayashi K, et al. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Clin Exp Nephrol. 2003;7(3):215-20.
113. Formosa V, Bellomo A, Iori A, et al. The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly. Arch Gerontol Geriatr. 2009;49 (Suppl 1):95-101.